CAR Cell-Derived Exosomes in Cancer Therapy: Biogenesis, Engineering Strategies and Antitumor Mechanisms

Area of Science:

• Oncology
• Immunotherapy
• Nanomedicine

Background:

• Chimeric antigen receptor (CAR) cell therapy, including CAR T, CAR NK, and CAR macrophage cells, is effective against tumors, especially hematologic malignancies.
• CAR cell therapy faces manufacturing challenges and risks serious adverse events like cytokine release syndrome (CRS).
• Exosomes derived from CAR cells offer potential advantages over traditional CAR cell therapy.

Purpose of the Study:

• To review the biogenesis, engineering, and antitumor mechanisms of CAR cell-derived exosomes.
• To discuss the clinical evidence and potential of CAR cell-derived exosomes in cancer therapeutics.
• To explore combination strategies of CAR cell-derived exosomes with other antitumor modalities.

Main Methods:

• Review of existing literature on CAR cell-derived exosomes.
• Analysis of biogenesis pathways and engineering strategies for exosome modification.
• Evaluation of preclinical and clinical data on antitumor efficacy and safety.

Main Results:

• CAR cell-derived exosomes retain the tumor-killing functions of parent CAR cells.
• Exosomes offer practical benefits: availability, safety, and ease of storage/transport.
• Combinatorial approaches using CAR cell-derived exosomes enhance efficacy and reduce side effects.

Conclusions:

• CAR cell-derived exosomes represent a promising next-generation cancer therapeutic.
• Their inherent safety and versatility facilitate clinical translation and combination therapies.
• Further research and clinical studies are warranted to fully realize their therapeutic potential.